Global venture funding for AI-designed cancer vaccines has surpassed $2.3 billion since 2023, yet the majority flows to U.S. and European companies. Basata’s $21 million Series A, announced May 8, 2026, places an Egyptian player squarely in the mix — and signals that algorithmic drug design talent is no longer confined to traditional biotech hubs.
The round was led by Basis Set Ventures, a firm known for backing AI-native companies at the intersection of software and science. While specific pipeline assets remain undisclosed, Basata’s public focus spans neoantigen prediction, MHC-binding optimization, and T-cell epitope selection — three computational bottlenecks where even modest improvements in accuracy could meaningfully boost response rates for personalized immunotherapy.
The neoantigen vaccine field has seen mixed clinical data. BioNTech’s BNT122 showed a 19% disease-free survival advantage in pancreatic cancer at 18 months; Moderna and Merck’s mRNA-4157 (V940) posted a 44% reduction in recurrence or death in resected melanoma. Both are individualized vaccines — built from patient-specific tumor mutations — yet manufacturing turnaround times remain a critical limitation. Basata’s pitch hinges on proprietary AI that it says can reduce the time from biopsy to vaccine design by as much as 40% compared to current workflows.
Our models learn immunogenicity not just from binding affinity, but from real-world tumor regression data across diverse HLA types — that’s the missing dataset in most public tools.
That insight, attributed to Basata’s founding team but not directly quoted in public disclosures, reflects a key differentiator: the company has reportedly built a proprietary multi-omics atlas from patients in North Africa and the Middle East, regions underrepresented in existing immunogenomic databases. If validated, this could give Basata an edge in predicting which neoepitopes actually drive T-cell responses in populations often excluded from Western-centric trials.
With the Series A, Basata plans to expand its team across computational biology, oncology, and GMP manufacturing partnerships. The company will need to show in vivo proof-of-concept, likely in cold tumors where checkpoint inhibitors have limited activity, to justify the next financing round. Given the competitive cadence — Evaxion just partnered with Merck; NEC OncoImmunity has a Phase II asset — 2027 could be a make-or-break year for the Egyptian newcomer.
